Get to know our clinical trials
A randomized, open-label Phase 3 clinical trial to evaluate darovasertib as a neoadjuvant treatment in patients with non-metastatic primary uveal melanoma (OptimUM-10)
THE AIM OF THE STUDY IS TO DETERMINE WHETHER THE EXPERIMENTAL DRUG CALLED DAROVASERTIB (ALSO KNOWN AS IDE196) IS SAFE AND EFFECTIVE IN PEOPLE WITH A SPECIFIC TYPE OF EYE CANCER CALLED UVEAL MELANOMA (UM).
Technical Summary
- A RANDOMIZED, OPEN-LABEL PHASE 3 CLINICAL TRIAL TO EVALUATE DAROVASERTIB AS A NEOADJUVANT TREATMENT IN PATIENTS WITH NON-METASTATIC PRIMARY UVEAL MELANOMA (OPTIMUM-10)
- Code EudraCT: 2025-522387-32
- Protocol number: IDE196-010
- Promoter: IDEAYA Biosciences, Inc.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.